Aromatase inhibitors for breast cancer prevention

Saranya Chumsri, Stephen Yu, Amanda Schech, Gauri Sabnis, Angela Brodie

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

Original languageEnglish (US)
Title of host publicationTrends in Breast Cancer Prevention
PublisherSpringer International Publishing
Pages103-111
Number of pages9
ISBN (Electronic)9783319271354
ISBN (Print)9783319271330
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Chemoprevention

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chumsri, S., Yu, S., Schech, A., Sabnis, G., & Brodie, A. (2016). Aromatase inhibitors for breast cancer prevention. In Trends in Breast Cancer Prevention (pp. 103-111). Springer International Publishing. https://doi.org/10.1007/978-3-319-27135-4_5